Sitagliptin

Drug Profile

Sitagliptin

Alternative Names: Glactiv; Januvia; MK-0431; MK-431; ONO-5435; Tesavel; Xelevia

Latest Information Update: 16 Dec 2016

Price : $50

At a glance

  • Originator Merck & Co; Merck Sharp & Dohme
  • Developer Banyu; Merck & Co; Merck Sharp & Dohme; Ono Pharmaceutical; Pfizer; University of Colorado at Denver; Washington University School of Medicine
  • Class Antihyperglycaemics; Pyrazines; Small molecules; Triazoles
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Discontinued Type 1 diabetes mellitus

Most Recent Events

  • 01 Nov 2016 Merck completes a phase-III trial in Type-2 diabetes mellitus (Adjunctive treatment) in Japan (NCT02577016)
  • 01 Sep 2016 Merck and Duke University Medical Center initiates a phase I trial for Type-2 diabetes in healthy volunteers in USA (NCT02683187)
  • 16 Aug 2016 Launched for Type-2 diabetes mellitus in Chile (PO) before August 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top